Stock Evaluator: DBV Technologies S.A. (DBVT)

DBV Technologies S.A. DBVT

$9.45 -0.23 -2.38%
November 19, 2026 3:16:08 PM EST November 10, 2021 Volume: 221,552
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Commentary & Analysis


Financial Summary

Share Statistics DBVT Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $603.0 $213.9 41%
Shares Out (Mil) 451.0 55.4 87%
Institutional Ownership 99.9% 93.3% 96%
Float (Mil) 207.5 40.6 74%
Beta -0.22 0.98 2%
Avg Daily Volume (000s) 264 597 48%
Price Change
(52-week)
(28.2%) 40.9% 31%
Growth DBVT Industry
Median
Percentile
(All Stocks)
Sales (5yr) (13.1%) 13.2% 4%
Net Income (5yr) 1.6% (10.7%) 42%
EPS (5yr) 18.6% 15.5% 66
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 80.8% (15.7%) 97%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 5 5
Current EPS ($0.127) ($0.454) ($0.379)
Month Ago EPS ($0.164) ($0.383) ($0.163)
# Rev Up 1 0 0
# Rev Down 0 1 1
Three Months Ago EPS ($0.163) ($0.377) ($0.160)
Year/Year Chg (11.2%) (56.9%) (84.5%)
Financials DBVT Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $4 $39 5%
Net Income (TTM) (Mil) ($207) ($44) 6%
EPS (TTM) ($0.559) ($1.400) 26%
Operating Cash Flow (TTM) (Mil) ($188) ($34) 4%
Net Cash Flow (TTM) (Mil) $96 $-0 77%
Long-Term Debt (Q1) (Mil) $7 $4 26%
Enterprise Value (Q1) (Mil) $415 $135 33%
Valuation DBVT Industry
Median
Percentile
(All Stocks)
P/B 20.60 1.97 96%
P/E na 17.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.8 na
Ratios DBVT Industry
Median
Percentile
(All Stocks)
Gross Margin 100.0% 67.9% 96%
Net Margin na (50.8%) na
ROA (127.2%) (47.5%) 4%
ROE (205.9%) (51.9%) 4%
Liabilities to Assets 31.0% 29.7% 22%
F-Score 4 3 33%

Passing Stock Screens

As of 11/18/2026, from a list of 60 stock screening strategies, DBVT meetings the criteria of 2 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors